OSA is common and independently associated with hypertension and increased arterial stiffness in consecutive perimenopausal women

Author(s): Pedrosa RP, Barros IM, Drager LF, Bittencourt MS, Medeiros AK, et al.

Abstract

Background:Perimenopause is associated with increased cardiovascular risk. OSA is an emerging risk factor for cardiovascular disease, particularly among men, but the independent contribution of OSA to cardiovascular risk in climacteric women is not clear.

Methods:We evaluated 277 consecutive women (age, 56 [52-61] years; BMI, 28 [25-32] kg/m2) without manifest cardiovascular disease (heart failure, coronary disease, or stroke). All women underwent 24-h ambulatory BP monitoring, arterial stiffness evaluation (pulse wave velocity), and portable sleep study.

Results:OSA (apnea-hypopnea index ≥ 5 events/h) and moderate to severe OSA (apnea-hypopnea index ≥ 15 events/h) were diagnosed in 111 (40.1%) and 31 (11.1%) women, respectively. None of the participants had received a previous diagnosis of OSA. Women with moderate to severe OSA vs those without OSA had a higher prevalence of hypertension, were prescribed more medications for hypertension, had higher awake BP (systolic, 133 [125-142] vs 126 [119-134] mm Hg [P < .01]; diastolic, 82 [78-88] vs 79 [74-85] mm Hg [P = .07]), higher nocturnal BP (systolic, 125 [118-135] vs 115 [109-124] mm Hg [P < .01]; diastolic, 73 [69-79] vs 69 [62-75] mm Hg [P < .01]), and more arterial stiffness (pulse wave velocity, 11.5 [10.1-12.3] m/s vs 9.5 [8.6-10.8] m/s, P < .001). Oxygen desaturation index during the night was independently associated with 24-h arterial BP and arterial stiffness (per five-unit increase in oxygen desaturation index, β = 1.30 [95% CI, 0.02-2.54; P = .04] vs 0.22 [95% CI, 0.03-0.40; P = .02] in women with vs without OSA, respectively).

Conclusions:OSA is common, underdiagnosed, and independently associated with high BP and increased arterial stiffness in perimenopausal women.

Similar Articles

Safety of intravenous immunoglobulin (IVIG) therapy

Author(s): Katz U, Achiron A, Sherer Y, Shoenfeld Y

Intravenous immunoglobulin: adverse effects and safe administration

Author(s): Orbach H, Katz U, Sherer Y, Shoenfeld Y

Complications of intravenous immune globulin treatment in neurologic disease

Author(s): Brannagan TH 3rd, Nagle KJ, Lange DJ, Rowland LP

Adverse effect of polyvalent immunoglobulin in the treatment of Guillain-Barre syndrome

Author(s): Chamouni P, Tamion F, Gueit I, Girault C, Lenain P, et al.

Patient demographics and health plan paid costs in chronic inflammatory demyelinating polyneuropathy

Author(s): Guptill JT, Bromberg MB, Zhu L, Sharma BK, Thompson AR, et al.

Diffuse muscular coactivation [DMC] as a potential source of pain in fibromyalgia -- part 1

Author(s): Donaldson CC, Snelling LS, MacInnis AL, Sella GE, Mueller HH

Pregabalin for fibromyalgia: some relief but no cure

Author(s): Kim L, Lipton S, Deodhar A

The effects of pregabalin on sleep disturbance symptoms among individuals with fibromyalgia syndrome

Author(s): Russell IJ, Crofford LJ, Leon T, Cappelleri JC, Bushmakin AG, et al.

The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia

Author(s): Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, et al.

Prevalence and factors associated with fibromyalgia in Mexican patients with systemic lupus erythematosus

Author(s): Valencia-Flores M, Cardiel MH, Santiago V, Resendiz M, Castaño VA, et al.

The prevalence and characteristics of fibromyalgia in the general population

Author(s): Wolfe F, Ross K, Anderson J, Russell IJ, Hebert L

Estimates of the prevalence of arthritis and other rheumatic conditions in the United States

Author(s): Lawrence RC, Felson DT, Helmick CG, Arnold LM, Choi H, et al.

Prevalence of fibromyalgia in children: a clinical study of Mexican children

Author(s): Clark P, Burgos-Vargas R, Medina-Palma C, Lavielle P, Marina FF

Management of fibromyalgia syndrome

Author(s): Goldenberg DL, Burckhardt C, Crofford L

Fibromyalgia syndrome module at OMERACT 9: domain construct

Author(s): Mease P, Arnold LM, Choy EH, Clauw DJ, Crofford LJ, et al.

Toward development of a fibromyalgia responder index and disease activity score: OMERACT module update

Author(s): Mease PJ, Clauw DJ, Christensen R, Crofford LJ, Gendreau RM, et al.

Nerve ultrasound score in distinguishing chronic from acute inflammatory demyelinating polyneuropathy

Author(s): Kerasnoudis A, Pitarokoili K, Behrendt V, Gold R, Yoon MS

Clinical spectrum of chronic acquired demyelinating polyneuropathies

Author(s): Saperstein DS, Katz JS, Amato AA, Barohn RJ

Chronic inflammatory demyelinating polyradiculoneuropathy

Author(s): Barohn RJ, Kissel JT, Warmolts JR, Mendell JR

Chronic inflammatory polyradiculoneuropathy

Author(s): Dyck PJ, Lais AC, Ohta M, Bastron JA, Okazaki H, et al.

Derivation and validation of diagnostic criteria for chronic inflammatory demyelinating polyneuropathy

Author(s): Koski CL, Baumgarten M, Magder LS, Barohn RJ, Goldstein J, et al.

IVIG regulates BAFF expression in patients with chronic inflammatory demyelinating polyneuropathy (CIDP)

Author(s): Ritter C, Förster D, Albrecht P, Hartung HP, Kieseier BC, et al.

Immunosuppressive treatment in refractory chronic inflammatory demyelinating polyradiculoneuropathy

Author(s): Cocito D, Grimaldi S, Paolasso I, Falcone Y, Antonini G, et al.

High prevalence of restless legs syndrome among patients with fibromyalgia: a controlled cross-sectional study

Author(s): Viola-Saltzman M, Watson NF, Bogart A, Goldberg J, Buchwald D